TESAMORELIN
GH RELEASING HORMONE
- Molecular Formula:C221H366N72O67S
- Molecular Weight: 5135.77
- Sequence: trans-hexenoyl-acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-LeuGln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
DESCRIPTION
Tesamorelin is a growth hormone releasing hormone analog that increases IGF-1levels in men and women, by an average of 181 micrograms/liter. It binds to andstimulates GHRH receptors with similar potency as endogenous GHRH. It has a hostof other benefits including nootropic effects and reducing triglycerides.Tesamorelin has subsequently been shown to decrease carotid intima-mediathickness (cIMT), visceral adipose tissue (VAT), and c-reactive protein (CRP). It hasnot been linked to significantly affect other pituitary hormones and their respectivemechanisms in the body. Additionally, it can improve cognitive function for healthyseniors and patients with an increased risk of Alzheimer’s disease, due to mildcognitive impairment.
PROTOCOL
- Content & Potency: 1mg lyophilized subcutaneous injectables presented in aquantity of 24 vials with 10ml of sterile water for injection for reconstitution.
- Suggested dosage: Reconstitute each vial prior to injection with 0.6ml sterile waterfor injection, inject 0.5ml subcutaneously before bed 6 out of 7 days 90 minutes afterlast food intake.
CLINICAL RESEARCH
Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GHPulsatility and Insulin Sensitivity in Health Man
Takara L. Stanley, Cindy Y. Chen, Karen L. Branch, Hideo Makimura, and Steven K.Grinspoon Program in Nutritional Metabolism and Neuroendocrine Unit (T.L.S., C.Y.C.,H.M., S.K.G.) and the Clinical Research Center (K.L.B.), Massachusetts General Hospitaland Harvard Medical School, Boston, Massachusetts 02114
Background: Strategies to augment pulsatile GH may be beneficial in patients withexcess visceral adiposity, in whom GH secretion is reduced. The objective of thisstudy was to determine the effects of a novel GHRH (GHRH1 – 44) analog,tesamorelin, on endogenous GH pul- satility and insulin sensitivity in healthy men.
Methods: Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2kg/m2) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made atbaseline, after 2 wk of treatment, and after 2 wk of withdrawal. The primary endpoint was change in mean overnight GH as determined by overnight frequentsampling. Secondary end points included insulin-stimulated glucose uptake asmeasured by euglycemic hyperinsulinemic clamp; IGF-I; and GH secretionparameters, including pulse area, pulse frequency, and basal secretion.
Results: Tesamorelin treatment increased mean overnight GH (change +0.5 ± 0.1μ,g/liter, P = 0.004), average log10 GH peak area (change +0.4 ± 0.1 log10μ,g/liter, P = 0.001), and basal GH secretion (change +0.008 ± 0.003 μ,g/liter · min,P = 0.008). IGF-I increased by 181 ± 22 μ,g/liter (P < 0.0001). Neither fastingglucose (P = 0.93) nor insulin-stimulated glucose uptake (P+ 0.61) wassignificantly affected by tesamorelin.
Conclusion: Once-daily short-term treatment with a GHRH1– 44 analog,tesamorelin, augments basal and pulsatile GH secretion. Moreover, althoughtesamorelin significantly increase IGF-I, peripheral insulin-stimulated glucoseuptake appears to be preserved. (J Clin Endocrinol Metab 96: 150 –158, 2011).
Here are some reliable URLs where you can find information about Tesamorelin:
- The National Center for Biotechnology Information (NCBI) website has a comprehensive database of scientific research articles, including those related to Tesamorelin. Link: https://www.ncbi.nlm.nih.gov/bioproject/?term=tesamorelin.
- The FDA website provides information on Tesamorelin, including its approved uses and safety profile. Link: https://www.fda.gov/search?s=tesamorelin
- The PubChem database provides information on the chemical properties of Tesamorelin, including its molecular structure, physical properties, and toxicity data. Link: https://pubchem.ncbi.nlm.nih.gov/compound/16137828
Please note that the information on these websites should be used for informational purposes only and should not be substituted for professional medical advice.
POPULAR
Peptide pages
BPC-157
BPC-157 Molecular Formula: C62H98N16O22 Molecular Weight: 1419.5355 Sequence: L-Valine,glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-;glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyllysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine DESCRIPTION Pentadecapeptide BPC-157, composed of 15 amino acids, is a partial sequence of body protection compound
Aminophylline
Aminophylline Molecular Formula: C16H24N10O4 Molecular Weight: 470.69 g/mol Sequence: Non-Peptide DESCRIPTION Aminophylline and glycyrrhetinic acid transdermal cream is used for fat loss. Aminophylline and glycyrrhetinic
SARMS LGD-4033
SARMS LGD-4033 SELECTIVE ANDROGEN RECEPTORMODULATOR Molecular Formula: C14H12F6N2O Molecular Weight: 338.25/mol Sequence:: Non-Peptide DESCRIPTION Selective Androgen Receptor Modulators (SARMs) provide the benefits of traditional anabolic/androgenic
